WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 22, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 15, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 29, 2022 , and in connection with the previously announced appointment of Michael J.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles , MD, has been appointed Executive Vice President, Research, Development, and
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 28, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , PhD, Senior Vice President and Chief Financial Officer (CFO), is on leave under
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 27, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 41 st Annual J.P.
Broad Anti-Leukemia Activity in Relapsed/Refractory and Frontline AML Presented in Oral Session Recommended Phase 2 Dose Well-Tolerated; Determination of Optimal Venclexta Duration Ongoing in Separate Cohorts WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 10, 2022-- ImmunoGen, Inc.
Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 9, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2022 , the compensation committee of the Company’s Board of Directors approved grants